Lantus Solostar insulin pen supply constraints reported despite lack of official FDA shortage status

Patients are experiencing difficulty sourcing Lantus Solostar insulin pens, even as the FDA has not formally declared a shortage. The supply strain is exacerbated by the market exit of competing insulin products, creating potential access risks for diabetic patients.